Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Secondly as pointed out by Sulentic
2023-09-06

Secondly, as pointed out by Sulentic and Kaminski in their recent paper [90], most of the AhR literature to date has focused on mouse AhR. Although both mouse and human AhR are interchangeable in many in vitro systems, the in vivo ligand binding affinity is drastically different between the two AhRs
-
br Discussion With recently improved understanding
2023-09-06

Discussion With recently improved understanding of the role of βARK1 in the progression of HF and as a potential therapeutic target in HF, we explored the relationship between plasma βARK1, as a marker of chronic sympathetic overactivation, and physical symptoms in HF. Our main findings were 1) e
-
br Occurrence of Inosine in
2023-09-06

Occurrence of Inosine in RNA Inosine is widespread among various types of RNAs including transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA). Within these RNAs, inosine can appear in different locations as well. Table 1 lists examples
-
By promoting bundling and processive elongation of actin fil
2023-09-06

By promoting bundling and processive elongation of Vinpocetine filaments and inhibiting association of capping protein with filament barbed ends, Ena/VASP family proteins contribute to the dynamics of lamellipodia and filopodia [41] and maintenance of focal adhesions and tight junctions [42, 43]. A
-
Taken together our results indicated that LOX can be
2023-09-06

Taken together, our results indicated that 5-LOX can be induced in mice by MPTP injection, and the 5-LOX inhibitor MK-886 reduced the death of dopaminergic neurons. MK-886 also reduced the LTB4 FSLLRY-NH2 induced by MPTP. The development of the novel 5-LOX or FLAP inhibitors may provide a new thera
-
Since innate immune responses represent the first
2023-09-05

Since innate immune responses represent the first defense against incoming infectious microorganisms, they are particularly engaged during the early stages of viral infections. Many innate defense mechanisms rely on the engagement of pattern recognition receptors (PRRs) which are conserved, germ lin
-
IC values were obtained for an expanded version
2023-09-05

IC50 values were obtained for an expanded version of the fragment library using the previously described mobility shift assay. Subsequently, Ki values were estimated from IC50 values to allow better comparison of the activity against targets which were measured at different substrate concentrations
-
CK is considered a central controller of cellular energy
2023-09-05

CK is considered a central controller of cellular energy homeostasis that catalyzes the reversible transfer of a phosphoryl group from ATP to adenosine diphosphate (ADP) and creatine to produce PCr [5]. This enzyme builds up a large pool of rapidly diffusing PCr for temporal and spatial buffering of
-
br Acknowledgment This study was supported by Japan
2023-09-05

Acknowledgment This study was supported by Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) [grant number 15K15031]. Introduction Glioma is the leading malignancy of astrocyte origin in the brain. The most aggressive, invasive, and destructive glioma
-
br Experimental and computation Standard samples of
2023-09-05

Experimental and computation Standard samples of artemisinin (1) and artemether (2) were purchased from China National Institutes for Food and Drug Control. Their ECD spectra, at a concentration of 1.0–5.0mg/mL in ethanol, were recorded in a quartz cuvette of 1mm optical path length using a Jasco
-
Previous studies demonstrate that chiral
2023-09-05

Previous studies demonstrate that chiral biointerface has great influence on cells adhesion and proteins adsorption [39], [40], [41], [42], [43], which inspired us to further develop antimicrobial materials or surfaces by taking advantage of the “chiral taste” of microbes. L-borneol is a hydrophobic
-
Fig shows a possible scheme of
2023-09-05

Fig. 8 shows a possible scheme of the generation of AP(+)-exosomes based on this study. In response to inflammatory stimuli, ERAP1 is secreted from ER into the extracellular milieu through the conventional secretion pathway. On the other hand, exosomes are derived from the endosomal pathway, and are
-
Volatile esters are important to wine quality
2023-09-05

Volatile esters are important to wine quality and to fresh berry grape flavor, especially in fox grapes (V. labrusca) [16]. Volatile esters such as Z-3-hexyl acetate can be found in V. vinifera ‘Cabernet Sauvignon’ berries albeit at low levels and their accumulation diminishes to below detection lev
-
br Serine glycine and one carbon metabolism Altered serine m
2023-09-05

Serine/glycine and one-carbon metabolism Altered serine metabolism in tumors was noted nearly half a century ago, and elevated flux through the de novo serine synthesis pathway (SSP) is a common phenomenon in cancer 7ACC2 receptor [43]. The SSP branches from glycolysis at the point of 3-phosphog
-
For patients who have taken
2023-09-05

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
16514 records 312/1101 page Previous Next First page 上5页 311312313314315 下5页 Last page